Arch Therapeutics Inc ARTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.16
- Day Range
- $1.16–1.20
- 52-Week Range
- $0.39–18.00
- Bid/Ask
- $1.12 / $1.45
- Market Cap
- $5.60 Mil
- Volume/Avg
- 6,885 / 3,839
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 38.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 8
- Website
- https://www.archtherapeutics.com
Valuation
|
Metric
|
ARTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 38.16 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARTH
|
|---|---|
Quick Ratio | 0.02 |
Current Ratio | 0.16 |
Interest Coverage | −1.09 |
Quick Ratio
ARTH
Profitability
|
Metric
|
ARTH
|
|---|---|
Return on Assets (Normalized) | −444.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ARTH
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nqsswqvlc | Shfx | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wjqlvcyj | Ggttv | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hxsqsjynw | Mvflgyx | $98.1 Bil | |
MRNA
| Moderna Inc | Bxrcdfbt | Pjqkc | $39.7 Bil | |
ARGX
| argenx SE ADR | Zddgrwpm | Zrlgl | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Jbhtmdyvt | Pkqzk | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lcnpgbv | Ysjqlx | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xvdcxhy | Hsgrxr | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Msffqxlzx | Qsqxb | $12.5 Bil | |
INCY
| Incyte Corp | Kypzqry | Ywnrrd | $11.8 Bil |